VIRIVirios Therapeutics, Inc.

Nasdaq virios.com


$ 0.18 $ -0.02 (-11.59 %)    

Thursday, 23-May-2024 14:57:56 EDT
QQQ $ 454.82 $ -8.61 (-1.87 %)
DIA $ 398.57 $ -6.59 (-1.66 %)
SPY $ 530.36 $ -8.03 (-1.51 %)
TLT $ 91.26 $ -0.61 (-0.66 %)
GLD $ 225.37 $ -3.16 (-1.44 %)
$ 0.2036
$ 0.19
$ 0.00 x 0
$ 0.00 x 0
$ 0.18 - $ 0.19
$ 0.18 - $ 2.42
963,175
na
3.92M
$ 1.90
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-01-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-14-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-18-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-23-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 virios-therapeutics-inc-to-offer-85m-shares-of-common-stock-at-020-per-share

- SEC Filing

 reported-earlier-virios-therapeutics-prices-17m-public-offering-of-85m-common-stock-to-commence-preparations-for-planned-imc-2-long-covid-phase-2b-study-at-020share

Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company" or "Virios Therapeutics"), a development-stage biotechno...

 virios-therapeutics-announces-21m-proposed-public-offering-of-common-stock

Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company" or "Virios Therapeutics"), a development-stage biotechno...

 virios-therapeutics-q1-2024-gaap-eps-007-misses-004-estimate

Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of...

 virios-therapeutics-announces-publication-of-international-patent-for-imc-2-covering-antiviral-treatment-of-long-covid

- New patent would extend coverage and expand potential value of Virios' antiviral pipeline globally –- Active Long-COVID c...

 virios-therapeutics-q4-2023-gaap-eps-006-beats-009-estimate

Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $...

 virios-therapeutics-issues-shareholder-letter-highlighting-corporate-progress-and-key-upcoming-milestones-all-of-virios-employees-have-agreed-to-a-10-salary-compensation-reduction-in-exchange-for-future-vesting-stock-options

Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION